{"id":"ipi3-nivo1","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The ICOS agonist component (IPI3) activates CD4+ and CD8+ T cells through the inducible T-cell co-stimulator pathway, promoting T-cell proliferation and effector function. Nivolumab (NIVO1), a PD-1 inhibitor, blocks the PD-1/PD-L1 checkpoint interaction that normally suppresses T-cell activity. Together, this dual mechanism aims to generate a more robust and durable anti-tumor immune response than either agent alone.","oneSentence":"IPI3/NIVO1 is a combination of an inducible T-cell co-stimulator (ICOS) agonist and a PD-1 inhibitor that enhances anti-tumor immune responses by activating T cells while removing inhibitory checkpoint signals.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:49.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic melanoma"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06519266","phase":"PHASE3","title":"PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2024-06-10","conditions":"Uveal Melanoma, Liver Metastases","enrollment":40},{"nctId":"NCT02977052","phase":"PHASE2","title":"Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab","status":"UNKNOWN","sponsor":"The Netherlands Cancer Institute","startDate":"2016-11-24","conditions":"Malignant Melanoma Stage III","enrollment":186},{"nctId":"NCT03219775","phase":"PHASE2","title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma","status":"UNKNOWN","sponsor":"AIO-Studien-gGmbH","startDate":"2017-07-06","conditions":"Transitional Cell Carcinoma, Advanced Cancer, Metastatic Cancer","enrollment":169}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ipilimumab 3 mg/kg","Nivolumab 1 mg/kg"],"phase":"phase_3","status":"active","brandName":"IPI3/NIVO1","genericName":"IPI3/NIVO1","companyName":"Vastra Gotaland Region","companyId":"vastra-gotaland-region","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IPI3/NIVO1 is a combination of an inducible T-cell co-stimulator (ICOS) agonist and a PD-1 inhibitor that enhances anti-tumor immune responses by activating T cells while removing inhibitory checkpoint signals. Used for Advanced or metastatic melanoma, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}